Etiology of Valvular Heart Disease-genetic and Developmental Origins

Overview

Journal Circ J

Specialty Cardiology & Vascular Diseases

Date 2014 Jul 8

PMID 24998280

Citations 26

Authors

Joy Lincoln

Vidu Garg

Affiliations

Soon will be listed here.

Abstract

Valvular heart disease occurs as either a congenital or acquired condition and advances in medical care have resulted in valve disease becoming increasingly prevalent. Unfortunately, treatments remain inadequate because of our limited understanding of the genetic and molecular etiology of diseases affecting the heart valves. Therefore, surgical repair or replacement remains the most effective option, which comes with additional complications and no guarantee of life-long success. Over the past decade, there have been significant advances in our understanding of cardiac valve development and, not surprisingly, mutations in these developmental genes have been identified in humans with congenital valve malformations. Concurrently, there has been a greater realization that acquired valve disease is not simply a degenerative process. Molecular investigation of acquired valve disease has identified that numerous signaling pathways critical for normal valve development are re-expressed in diseased valves. This review will discuss recent advances in our understanding of the development of the heart valves, as well as the implications of these findings on the genetics of congenital and acquired valvular heart disease.

Citing Articles

High-Throughput Metabolomics Applications in Pathogenesis and Diagnosis of Valvular Heart Disease.

Mutithu D, Kirwan J, Adeola H, Aremu O, Lumngwena E, Wiesner L Rev Cardiovasc Med. 2024; 24(6):169.

PMID: 39077521 PMC: 11264134. DOI: 10.31083/j.rcm2406169.

is a mechanosensitive transcription factor gene required for cardiac valve morphogenesis.

Ribeiro da Silva A, Gunawan F, Boezio G, Faure E, Theron A, Avierinos J Sci Adv. 2024; 10(20):eadl0633.

PMID: 38748804 PMC: 11095463. DOI: 10.1126/sciadv.adl0633.

A study protocol to characterise pathophysiological and molecular markers of rheumatic heart disease and degenerative aortic stenosis using multiparametric cardiovascular imaging and multiomics techniques.

Mutithu D, Aremu O, Mokaila D, Bana T, Familusi M, Taylor L PLoS One. 2024; 19(5):e0303496.

PMID: 38739622 PMC: 11090351. DOI: 10.1371/journal.pone.0303496.

Congenital aortic valve stenosis: from pathophysiology to molecular genetics and the need for novel therapeutics.

Yasuhara J, Schultz K, Bigelow A, Garg V Front Cardiovasc Med. 2023; 10:1142707.

PMID: 37187784 PMC: 10175644. DOI: 10.3389/fcvm.2023.1142707.

Comprehensive Analysis of Mitochondrial Dynamics Alterations in Heart Diseases.

Morciano G, Boncompagni C, Ramaccini D, Pedriali G, Bouhamida E, Tremoli E Int J Mol Sci. 2023; 24(4).

PMID: 36834825 PMC: 9961104. DOI: 10.3390/ijms24043414.

References

Laforest B, Andelfinger G, Nemer M . Loss of Gata5 in mice leads to bicuspid aortic valve. J Clin Invest. 2011; 121(7):2876-87. PMC: 3223824. DOI: 10.1172/JCI44555. View

Stankunas K, Ma G, Kuhnert F, Kuo C, Chang C . VEGF signaling has distinct spatiotemporal roles during heart valve development. Dev Biol. 2010; 347(2):325-36. PMC: 2958084. DOI: 10.1016/j.ydbio.2010.08.030. View

Sauls K, de Vlaming A, Harris B, Williams K, Wessels A, Levine R . Developmental basis for filamin-A-associated myxomatous mitral valve disease. Cardiovasc Res. 2012; 96(1):109-19. PMC: 3444235. DOI: 10.1093/cvr/cvs238. View

Barnette D, Hulin A, Ishtiaq Ahmed A, Colige A, Azhar M, Lincoln J . Tgfβ-Smad and MAPK signaling mediate scleraxis and proteoglycan expression in heart valves. J Mol Cell Cardiol. 2013; 65:137-46. PMC: 3869408. DOI: 10.1016/j.yjmcc.2013.10.007. View

Bonachea E, Chang S, Zender G, LaHaye S, Fitzgerald-Butt S, McBride K . Rare GATA5 sequence variants identified in individuals with bicuspid aortic valve. Pediatr Res. 2014; 76(2):211-6. PMC: 5717758. DOI: 10.1038/pr.2014.67. View

Cano A, Perez-Moreno M, Rodrigo I, Locascio A, Blanco M, del Barrio M . The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol. 2000; 2(2):76-83. DOI: 10.1038/35000025. View

Bella J, Tang W, Kraja A, Rao D, Hunt S, Miller M . Genome-wide linkage mapping for valve calcification susceptibility loci in hypertensive sibships: the Hypertension Genetic Epidemiology Network Study. Hypertension. 2007; 49(3):453-60. DOI: 10.1161/01.HYP.0000256957.10242.75. View

Maeda K, Kuratani T, Mizote I, Shimamura K, Takeda Y, Torikai K . Early experiences of transcatheter aortic valve replacement in Japan. Circ J. 2012; 77(2):359-62. DOI: 10.1253/circj.cj-12-0650. View

Habashi J, Judge D, Holm T, Cohn R, Loeys B, Cooper T . Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science. 2006; 312(5770):117-21. PMC: 1482474. DOI: 10.1126/science.1124287. View

10.

de la Pompa J, Epstein J . Coordinating tissue interactions: Notch signaling in cardiac development and disease. Dev Cell. 2012; 22(2):244-54. PMC: 3285259. DOI: 10.1016/j.devcel.2012.01.014. View

11.

Peacock J, Huk D, Ediriweera H, Lincoln J . Sox9 transcriptionally represses Spp1 to prevent matrix mineralization in maturing heart valves and chondrocytes. PLoS One. 2011; 6(10):e26769. PMC: 3202586. DOI: 10.1371/journal.pone.0026769. View

12.

Wu B, Wang Y, Lui W, Langworthy M, Tompkins K, Hatzopoulos A . Nfatc1 coordinates valve endocardial cell lineage development required for heart valve formation. Circ Res. 2011; 109(2):183-92. PMC: 3132827. DOI: 10.1161/CIRCRESAHA.111.245035. View

13.

Alexopoulos A, Bravou V, Peroukides S, Kaklamanis L, Varakis J, Alexopoulos D . Bone regulatory factors NFATc1 and Osterix in human calcific aortic valves. Int J Cardiol. 2008; 139(2):142-9. DOI: 10.1016/j.ijcard.2008.10.014. View

14.

Combs M, Yutzey K . Heart valve development: regulatory networks in development and disease. Circ Res. 2009; 105(5):408-21. PMC: 2777683. DOI: 10.1161/CIRCRESAHA.109.201566. View

15.

Hurlstone A, Haramis A, Wienholds E, Begthel H, Korving J, van Eeden F . The Wnt/beta-catenin pathway regulates cardiac valve formation. Nature. 2003; 425(6958):633-7. DOI: 10.1038/nature02028. View

16.

Caira F, Stock S, Gleason T, McGee E, Huang J, Bonow R . Human degenerative valve disease is associated with up-regulation of low-density lipoprotein receptor-related protein 5 receptor-mediated bone formation. J Am Coll Cardiol. 2006; 47(8):1707-12. PMC: 3951851. DOI: 10.1016/j.jacc.2006.02.040. View

17.

Thanassoulis G, Campbell C, Owens D, Smith J, Smith A, Peloso G . Genetic associations with valvular calcification and aortic stenosis. N Engl J Med. 2013; 368(6):503-12. PMC: 3766627. DOI: 10.1056/NEJMoa1109034. View

18.

Liebner S, Cattelino A, Gallini R, Rudini N, Iurlaro M, Piccolo S . Beta-catenin is required for endothelial-mesenchymal transformation during heart cushion development in the mouse. J Cell Biol. 2004; 166(3):359-67. PMC: 2172268. DOI: 10.1083/jcb.200403050. View

19.

Kyndt F, Gueffet J, Probst V, Jaafar P, Legendre A, LE Bouffant F . Mutations in the gene encoding filamin A as a cause for familial cardiac valvular dystrophy. Circulation. 2006; 115(1):40-9. DOI: 10.1161/CIRCULATIONAHA.106.622621. View

20.

Fernandez B, Duran A, Fernandez-Gallego T, Fernandez M, Such M, Arque J . Bicuspid aortic valves with different spatial orientations of the leaflets are distinct etiological entities. J Am Coll Cardiol. 2009; 54(24):2312-8. DOI: 10.1016/j.jacc.2009.07.044. View